HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients
Open Access
- 28 June 2000
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 283 (24), 3211-3216
- https://doi.org/10.1001/jama.283.24.3211
Abstract
Osteoporosis affects 20% of women older than 50 years and an even larger proportion of elderly women; fractures attributable to osteoporosis occur in approximately 1.5 million Americans annually.1-3 Although several recently approved medications effectively prevent and treat osteoporosis, no currently approved drug has been shown to stimulate bone formation activity by osteoblasts.4Keywords
This publication has 14 references indexed in Scilit:
- Stimulation of Bone Formation in Vitro and in Rodents by StatinsScience, 1999
- The pharmacology of bisphosphonates and new insights into their mechanisms of actionJournal of Bone and Mineral Research, 1999
- Physical Activity and Osteoporotic Fracture Risk in Older WomenAnnals of Internal Medicine, 1998
- Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including RasJournal of Bone and Mineral Research, 1998
- Healthy behaviors among women in the United States and Ontario: the effect on use of preventive care.American Journal of Public Health, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Prevalence of low femoral bone density in older U.S. women from NHANES IIIJournal of Bone and Mineral Research, 1995
- Perspective how many women have osteoporosis?Journal of Bone and Mineral Research, 1992
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data.American Journal of Public Health, 1988